BCL2L1 and T-cell non-Hodgkin lymphoma: Indeed, similar to our findings, low doses of DT2216 were found to kill BCLXL dependent T cell lymphomas in vitro and in vivo as well as T−cell acute lymphoblastic leukemia cells (13, 24).